in reverse order, K: potential is only that, potential. Who doesn't appreciate potential? We need the trials to start already. What does it tell you that mayo /ctix are sitting around around waiting for a possible grant, who knows what chances? It tells you they have NO MONEY for a trial which would be a big deal if it can get off the ground. We do not need Leo to say they are applying for a grant with Mayo we need him to say they are starting a phase 2! This is BOGUS however promising. Yes and meanwhile we wait on ovarian p2 news...Why the wait. Guess what, people are dying, and CTIX cannot start its phase 2's. Of course you are right about the dosing issue as I have been harping on ad nauseum, and who knows how long it'll take to find the sweet spot as you call it. Wouldn't it be nicer to have experience with 3 or 4 or 5 patients iwth ovarian and pancreatic and renal cell CA at the proposed 3x weekly doses? You betcha. But no, not in the cards apparently. Also: Karen- why would a paper saying what we already know about K be big deal? It won't be- no new data.
B: Interesting comment about the dosing. I am a bit surprised too. Maybe they have other data? Very likely a success as we all expect. My very strong belief, now that they have freeze dried the stuff- infectious disease specialists convene to discuss antibiotic stewardship which keeps the drug off the market for the time being, in a negotiated agreement with Cellceutix. Would love to have some real ID experts weigh in on this, as the time comes. Your thoughts?
P- who knows. Appreciate that acetate and sulfate are different salts for abacavir.
B- OM. Sure, it'll be sensational if it works. I guess my own thought is that the run up is a prelude to news about B-OM and B-UP. But maybe that is too optimistic
